Prevention of bleeding in patients with atrial fibrillation undergoing PCI

New England Journal of Medicine

Volumn 375, Issue 25, 2016, Pages 2423-2434

  Gibson, C Michael ^a,k   Mehran, Roxana ^b   Bode, Christoph ^c   Halperin, Jonathan ^b   Verheugt, Freek W ^d   Wildgoose, Peter ^e   Birmingham, Mary ^e   Ianus, Phar Juliana ^e   Burton, Paul ^e   Van Eickels, Martin ^j   Korjian, Serge ^a   Daaboul, Yazan ^a   Lip, Gregory Y H ^g   Cohen, Marc ^f   Husted, Steen ^h   Peterson, Eric D ⁱ   Fox, A Keith ^j  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

^d BAYER PHARMA AG   (Germany)

^e JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^f NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^g UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^j ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^k BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; RIVAROXABAN; TICAGRELOR; WARFARIN; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; PURINERGIC P2Y RECEPTOR ANTAGONIST; VITAMIN K GROUP;

ADULT; AGED; ARTICLE; ATRIAL FIBRILLATION; BARE METAL STENT; BLEEDING; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY STENT; CORONARY STENTING; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONFIDENCE INTERVAL; HEMORRHAGE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; STENT;

AGED; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; CONFIDENCE INTERVALS; DRUG THERAPY, COMBINATION; FACTOR XA INHIBITORS; FEMALE; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RIVAROXABAN; STENTS; VITAMIN K;

EID: 85006457293     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1611594     Document Type: Article

References (13)

1. Rubboli A, Colletta M, Herzfeld J, Sangiorgio P, Di Pasquale G. Periprocedural and medium-term antithrombotic strategies in patients with an indication for long-term anticoagulation undergoing coronary angiography and intervention. Coron Artery Dis 2007;?18:?193-9.
2. Wang TY, Robinson LA, Ou FS, et al. Discharge antithrombotic strategies among patients with acute coronary syndrome previously on warfarin anticoagulation: physician practice in the CRUSADE registry. Am Heart J 2008;?155:?361-8.
3. Pérez-Gómez F, Alegría E, Berjón J, et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol 2004;?44:?1557-66.
4. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998;?339:?1665-71.
5. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;?367:?1903-12.
6. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;?12:?1360-420.
7. Paikin JS, Wright DS, Crowther MA, Mehta SR, Eikelboom JW. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation 2010;?121:?2067-70.
8. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;? 365:?883-91.
9. Mega JL, Braunwald E, Wiviott SD, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012;?366:?9-19.
10. Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013;? 381:?1107-15.
11. Gibson CM, Mehran R, Bode C, et al. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a doseadjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Am Heart J 2015;?169(4):?472-8.e5.
12. Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet 2009;?374:?29-38.
13. Popma CJ, Sheng S, Korjian S, et al. Lack of concordance between local investigators, angiographic core laboratory, and clinical event committee in the assessment of stent thrombosis: results from the TRACER angiographic substudy. Circ Cardiovasc Interv 2016;?9(5):?e003114.